Drugs in Dev. Infections and Infectious Diseases
Undisclosed
France 
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sanofi to Enroll Thousands for its Coronavirus Vaccine Trials
Details : Sanofi is working on two vaccine projects to prevent COVID-19. Of more than 100 vaccine candidates in development, 10 have reached the clinical testing stage so far.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
June 05, 2020
Lead Product(s) : COVID-19 Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Sanofi and Gsk to Join Forces in Unprecedented Vaccine Collaboration to Fight Covid-19
Details : Sanofi will contribute its S-protein COVID-19 antigen and GSK will contribute its proven pandemic adjuvant technology to the collaboration.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
April 14, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : GSK
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : SARS Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Collaboration
Sanofi joins forces with U.S. Department of Health for COVID-19
Details : Work with Biomedical Advanced Research and Development Authority (BARDA) will utilize Sanofi’s well-established recombinant technology platform to expedite a potential COVID-19 vaccine.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
February 18, 2020
Lead Product(s) : SARS Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Exosome-Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Bpifrance
Deal Size : $5.5 million
Deal Type : Funding
Details : These funds will be used notably for the development of a new generation of natural vaccines using exosomes to prevent SARS-CoV-2 infection, including the variants responsible for the severe form of Covid-19.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
August 03, 2022
Lead Product(s) : Exosome-Based Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Bpifrance
Deal Size : $5.5 million
Deal Type : Funding
Lead Product(s) : Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Batavia Bioscience
Deal Size : Undisclosed
Deal Type : Collaboration
Batavia Biosciences to Partner with Valneva Sweden AB for Polio Vaccine Development
Details : Under the terms of the agreement, Valneva will manufacture the sIPV vaccine for clinical trial purposes in its state-of-the-art GMP polio manufacturing facility operated under GAPIII[2] polio containment in Solna, Sweden, using Batavia’s process.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
June 16, 2020
Lead Product(s) : Inactivated Polio Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Batavia Bioscience
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : DuckCelt-T17
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Vaxxel
Deal Size : Undisclosed
Deal Type : Acquisition
Vaxxel Buys Transgene’s Cell Line to Develop New Vaccines
Details : Vaxxel has acquired Transgene’s DuckCelt T17 cell line to develop industrial-scale vaccines against respiratory viruses.
Product Name : DuckCelt-T17
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
April 05, 2020
Lead Product(s) : DuckCelt-T17
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Vaxxel
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Unitaid
Deal Size : $6.4 million
Deal Type : Funding
MedinCell Receives $ 6.4 Million Grant From Unitaid to Fight Malaria
Details : The grant aims to fund the formulation and preclinical activities of a 3-month acting injectable ivermectin to neutralize the transmission vector of Malaria.
Product Name : mdc-STM
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 25, 2020
Lead Product(s) : Ivermectin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Unitaid
Deal Size : $6.4 million
Deal Type : Funding
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The step was followed by the release of initial data from China suggesting a role of IL-6 in the development of Acute Respiratory Distress Syndrome as a result of COVID-19.
Product Name : Sylvant
Product Type : Antibody
Upfront Cash : Inapplicable
March 18, 2020
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : CARB-X
Deal Size : $4.4 million
Deal Type : Funding
Details : The funding is to support the development of Antabio's novel small molecule candidate for the treatment of Pseudomonas aeruginosa infections in Cystic Fibrosis (CF) patients.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 01, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : CARB-X
Deal Size : $4.4 million
Deal Type : Funding
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A third of patients with COVID-19 taking EUSA Pharma's interleukin (IL)-6 targeted monoclonal antibody siltuximab have experienced a clinical improvement, reveals a case-control trial in Italy.
Product Name : Sylvant
Product Type : Antibody
Upfront Cash : Inapplicable
January 04, 2020
Lead Product(s) : Siltuximab
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
